Kraig Biocraft Labs Inc - KBLB stock
About Kraig Biocraft[edit]
Kraig Biocraft Laboratories (OTC: KBLB) is a US-based biotechnology company that is mainly involved in the development and commercialization of spider silks.[1] The primary business of Kraig Biocraft Labs is to integrate DNA technology using genetically engineered silkworms that produce spider silk for the creation of speciality fibres and textiles. The fibres developed using such technologies are having greater strength, resiliency and flexibility for use in the specialty fiber and technical textile industries. The company believes that such materials would be superior to other materials available in the market.[2]
Research and Development[edit]
Kraig has developed around twenty distinct spider silk fibers through genetic engineering, following our genetic blueprints. A comprehensive scientific paper detailing one of the initial remarkable spider silk creations and our procedure for its development has undergone peer review and is now published in the prestigious scientific journal PNAS (the Journal of the National Academy of Sciences). We prefer to refer to these materials as genetically engineered spider silk rather than synthetic spider silk because they are not artificially created; instead, they are produced by genetically modified silkworms, and the resulting fiber is entirely composed of naturally produced silkworm protein. While they are not produced by spiders, these spider silks can be considered synthetic only in the sense that they are created by a far more efficient organism.[3]
Production[edit]
In 2024, the company signed a Memorandum of Understanding (MOU) with the Vietnam Sericulture Association and the Lam Dong Agro-Forestry Research Experiment Center, with the goal of producing products in Vietnam.[4] The agreement was completed a few months later and outlined Kraig's plans for expansion while LAREC provides expertise regarding the local climate impacts on breeding BAM-1 parental strains.[5]
Kraig has a facility in Vietnam, which was acquired in 2024. The facility is located in Lam Dong Province in an area that is known for silk production.[6] Production of BAM-1 recombinant spider silk hybrids began in June, 2024, following successful trials earlier in the year. The company expects to produce 10 time the amount produced during the trials.[7] The second wave of its production expansion was completed in 2024. The first phase, completed in July, provided space for operations during the rainy season. The second phase involved constructing a new production center, increasing rearing capacity by over eight times. The facility includes dedicated spaces for BAM-1 parental lines and a hybrid hatchery to support production through 2025.[8]
Leadership[edit]
The management team of Kraig Biocraft Labs includes Kim K. Thompson (Founder & CEO), and Jon Rice (COO). Before founding Kraig Biocraft, Mr. Thompson was an employee at Shearson, Lehman, Hutton where he specialized in equity trading and research of small-cap companies. He is also a member of the Triple Nine Society for persons with documented genius level IQs (having tested above the 99.9th percentile). Mr. Rice has over 13 years of experience in growing development stage businesses with a formal education in Chemical Engineering.[9]
Competition[edit]
The competitors of Kraig Biocraft Labs include AMSilk, Bolt Threads, and Spiber. The competitors of Kraig Biocraft mainly rely upon fermentation process for the production of silk which is extremely costly and also has a negative environmental impact. Based on the data shared by the company, they can produce silk for less than $300 per kilogram while the production of silk for their competitors ranges between $37,500-$137,500 per kilogram. This offers a huge cost advantage to Kraig Biocraft Labs. Additionally, the Spider Silk produced by Kraig Biocraft has very high strength and elasticity.[10]
Patents[edit]
On February 16, 2020, Kraig Biocraft Laboratories announced that the United State Patent and Trademark Office (USPTO) published two key patent applications filed by the Company. These two USPTO patent applications build on Kraig Labs' innovative recombinant spider silk technologies. The new patents open the possibility for large-scale production of materials such as elastin, keratin, human collagen, and many more at comparatively very low costs.[11]
Funding[edit]
January, 2025[edit]
In January, 2025, Kraig Biocraft secured a $10 million standby equity purchase agreement (SEPA) with YA II PN, Ltd. (Yorkville). The agreement allows the company to access capital over the next 36 months to support its spider silk production and commercialization. Kraig Labs is not obligated to use the funding and has no minimum use requirements or operational restrictions under the agreement.[12]
- ↑ Yahoo Finance. KBLB Stock Profile. Retrieved on 12/16/2023.
- ↑ kraiglabs.com. Spider Silk Company. Retrieved on 12/16/2023. Archive link.
- ↑ kraiglabs.com. Spider Silk. Retrieved on 12/16/2023. Archive link.
- ↑ Nasdaq.com. Kraig Biocraft Laboratories Signs Pivotal MOU in Vietnam's Silk Production Capital. January 30, 2024.
- ↑ BioSpace. Kraig Biocraft Laboratories Reports Signing Landmark Agreements in South East Asia. April 29, 2024.
- ↑ BioSpace. Kraig Biocraft Laboratories Announces New Spider Silk Production Facility in Vietnam’s Silk Capital. February 13, 2024.
- ↑ kraiglags.com. KRAIG BIOCRAFT LABORATORIES ANNOUNCES BAM-1 SPIDER SILK HYBRIDS ARE IN PRODUCTION. June 3, 2024.
- ↑ GlobeNewswire. Kraig Biocraft Laboratories Completes New Production Center, Expands Capacity more than Eightfold. September 9, 2024.
- ↑ kraiglabs.com. Management Team. Retrieved on 12/16/2023. Archive link.
- ↑ kraiglabs.com. Comparison. Retrieved on 12/16/2023. Archive link.
- ↑ Globe Newswire. USPTO Publishes Two Key Kraig Biocraft Laboratories Patent Applications. February 16, 2022.
- ↑ GlobeNewswire. Kraig Biocraft Laboratories Secures $10 Million SEPA to Support Spider Silk Production Growth and Commercialization. January 21, 2025.
OTC Symbol: KBLB | OTC Tier: OTCQB
